Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management
Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums.
Related Articles
International Journal of Cancer Symposium on Principles of Chromatin Remodeling in Cancer and Translational Perspectives
Welcome to the International Journal of Cancer Symposium on Principles of Chromatin Remodeling in Cancer and Translational Perspectives Tight regulation of the spatial and temporal…
Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL
Nature Reviews Clinical Oncology – Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL
Government to publish a National Cancer Plan, as recommended by Health and Social Care Committee – Committees – UK Parliament
The Government has said that it will be publishing a National Cancer Plan, as recommended by the predecessor Health and Social Care Committee.
Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis
Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.
Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL
Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.
Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL
Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.
Potential Biomarkers Positively Prognosticate Outcomes With Pembrolizumab Plus Chemo in High-Risk TNBC
Pembrolizumab plus chemotherapy conferred an efficacy advantage over chemotherapy alone in high-risk TNBC subgroups defined by potential biomarkers.
Brain Metastases: Study Shows Cognitive Recovery After… : Oncology Times
An abstract is unavailable.
Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma
The GPRC5D-targeting CAR T-cell therapy arlocabtagene autoleucel also yielded a 53% complete response rate in relapsed/refractory multiple myeloma.
Help Fund an Early-Career Researcher
Eighty-eight cents of every dollar you give does directly to cancer research. Cancer Research Saves Lives.
